Photo from wikipedia
The 21‐gene recurrence score (RS) assay predicts response to adjuvant chemotherapy in patients with early‐stage, hormone receptor‐positive, human epidermal growth factor receptor 2 (HER2)‐negative invasive breast cancer, but to the… Click to show full abstract
The 21‐gene recurrence score (RS) assay predicts response to adjuvant chemotherapy in patients with early‐stage, hormone receptor‐positive, human epidermal growth factor receptor 2 (HER2)‐negative invasive breast cancer, but to the authors' knowledge, the role of the assay in guiding the selection of chemotherapy regimen has not been established. The current study was conducted to examine patterns of use of the RS assay for selecting chemotherapy regimens across a statewide registry from 2006 through 2013.
Journal Title: Cancer
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!